Webinar
Webinar
Webinar

prIME News: Live Monthly Updates in Immuno-Oncology

Not a member of My prIME? Join now for instant access.

We are pleased to invite you to participate in prIME News: Live Monthly Updates in Immuno-Oncology, a live, interactive online meeting series. Every month you can participate in a new Webinar featuring an expert speaking on recent updates in immunotherapy. You can access these Webinars through your desktop computer and tablet devices.

CME

CME

1.0 AMA PRA Category 1 Credit™

Looking Toward 2018—Where Are We Headed With Immunotherapy in Head and Neck Cancers?

Tuesday, December 12, 2017
7.00 AM – 8.00 AM Eastern Daylight Time
1.00 PM – 2.00 PM Central European Time

Robert Haddad, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, United States

Practical Application of Immunotherapy in Melanoma

Tuesday, November 14, 2017
7.00 AM – 8.00 AM Eastern Daylight Time
1.00 PM – 2.00 PM Central European Time

Caroline Robert, MD, PhD
Gustave Roussy
Villejuif, France

The Current State of Immunotherapy for Gastrointestinal Cancers

Tuesday, October 10, 2017
9.30 AM – 10.30 AM Eastern Daylight Time
3.30 PM – 4.30 PM Central European Time

Bert O’Neil, MD
Indiana University
Indianapolis, Indiana, United States

  • Robert Haddad, MDDana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Caroline Robert, MD, PhDGustave Roussy
    Villejuif, France
  • Bert O’Neil, MDIndiana University
    Indianapolis, Indiana, United States

This educational activity is designed to meet the needs of medical oncologists and other healthcare professionals involved in the treatment of patients with cancer.

After completion of this educational activity, participants should be able to:

  • Identify recent and emerging efficacy and safety data for immunotherapeutic strategies for the treatment of cancer
  • Explain the important features of patient selection for immunotherapies
  • Identify strategies to recognize and manage adverse events due to the use of immunotherapies

This educational activity is supported by a grant from Merck and Co, Inc.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this live online activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.